ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with ...
Tuesday saw a good slate of deals, including the acceleration of Ohio's $508.865 million of GOs and Austin's $419.035 million ...
The pharmaceutical industry is experiencing a profound transformation in how it approaches commercial decision-making and insights delivery with a big wave of technology and AI at the doorstep. Market ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral ...
Revenues: Revenue for the three months ended September 30, 2025 was $3.7 million, compared to $2.3 million in the same period in 2024. The increase of $1.4 million in revenue resulted from a $1.5 ...
Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...
Infinidat, a leading provider of enterprise storage solutions, today announced that the company has won three Top InfoSec Innovator Awards for 2025 from Cyber Defense Magazine, a leading information ...
As Trump shifts his tone on Chinese students, Beijing doubles down on AI education—signaling a new kind of cold war in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback